Design Therapeutics Announces Third Quarter 2026 Financial Results and Recent Business Updates
Globe Newswire•04/11/2026•16:01 ET
0
Key Highlights
- ➤$208.6 million cash and securities at September 30, 2026
- ➤DT-216P2 registrational plan update expected in Q4 2026
- ➤DT-216P2 12-week RESTORE-FA data expected in Q1 2027
- ➤$20.3 million third-quarter net loss versus $17.0 million
- ➤DT-818 Phase 1 data anticipated in 2027
Expert Statements
Pratik Shah, Chairperson and Chief Executive Officer of Design Therapeutics
“We remain focused on evaluating DT-216P2 over longer treatment durations and preparing for the next stage of clinical development in Friedreich ataxia”
Pratik Shah, Chairperson and Chief Executive Officer of Design Therapeutics
“In DM1, our Phase 1 trial of DT-818 is evaluating an approach designed to selectively reduce transcription of the mutant DMPK allele, targeting the source of toxic RNA.”
Pratik Shah, Chairperson and Chief Executive Officer of Design Therapeutics
“Clinical readouts expected in 2027 will help guide these programs as we pursue our vision for the GeneTAC(®) platform: to address the underlying causes of serious genetic diseases and deliver meaningful benefits for patients.”
DT-216P2 Anticipated Milestones: Registrational Plan Update in Q4 2026 and 12-Week RESTORE-FA Data in Q1 2027
Cash and securities of $208.6 million at quarter-end provide strong financial runway
Get started
Create a free account to read the full story.